SPOTLIGHT -
EP. 1: Introduction: Impact of Molecular Subtyping in Breast Cancer
EP. 2: Role of Genetic Testing in Breast Cancer
EP. 3: Pathologist's Role in Genetic Testing for Breast Cancer
EP. 4: Reviewing Key Genomic Assays in Breast Cancer
EP. 5: Predicting Risk of Recurrence in Breast Cancer
EP. 6: Pathology, Oncology Collaboration in Breast Cancer
EP. 7: Genetic Tests Offer New Tool for Tumor Assessment
EP. 8: Treating ER-Positive De Novo Metastatic Breast Cancer
EP. 9: CDK4/6 Inhibition in Metastatic Breast Cancer
EP. 10: Endocrine Therapy Resistance in Breast Cancer
EP. 11: Role of Bevacizumab in Breast Cancer
EP. 12: BOLERO-2: Everolimus Plus Exemestane in Resistant MBC
EP. 13: Pertuzumab in HER2-Positive Metastatic Breast Cancer
EP. 14: Role of T-DM1 in HER2-Positive Breast Cancer
EP. 15: Managing Brain Metastases in Breast Cancer
EP. 16: Standard Therapies for Triple-Negative Breast Cancer
EP. 17: Chemotherapeutics for Triple-Negative Breast Cancer
EP. 18: Future Treatments for Triple-Negative Breast Cancer
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
